

Identification of key candidate genes for pancreatic cancer by bioinformatics analysis

KUI LV, JIANYING YANG, JUNFENG SUN and JIANGUO GUAN

Department of Emergency Medicine, Anhui No. 2 Provincial People's Hospital,
Hefei, Anhui 230041, P.R. China

Received November 2, 2018; Accepted March 15, 2019

DOI: 10.3892/etm.2019.7619

Abstract. Although pancreatic cancer has the highest mortality rate among all neoplasms worldwide, its exact mechanism remains poorly understood. In the present study, three Gene Expression Omnibus (GEO) datasets were integrated to elucidate the potential genes and pathways that contribute to the development of pancreatic cancer. Initially, a total of 226 differentially expressed genes (DEGs) were identified in the three GEO datasets, containing 179 upregulated and 47 downregulated DEGs. Furthermore, function and pathway enrichment analyses were performed to explore the function and pathway of these genes, and the results indicated that the DEGs participated in extracellular matrix (ECM) processes. In addition, a protein-protein interaction network was constructed and 163 genes of the 229 DEGs were filtered into the network, resulting in a network complex of 163 nodes and 438 edges. Finally, 24 hub genes were identified in the network, and the top 2 most significant modules were selected for function and pathway analysis. The hub genes were involved in several processes, including activation of matrix, degradation of ECM and ECM organization. Taken collectively, the data demonstrated potential key genes and pathways in pancreatic cancer, which may provide novel insights to the mechanism of pancreatic cancer. In addition, these hub genes and pathways may be considered as targets for the treatment of pancreatic cancer.

Introduction

Pancreatic cancer is one of the most prevalent and lethal malignancies worldwide (1). Although substantial progress has been made in adjuvant and neo-adjuvant chemotherapies during previous decades, pancreatectomy remains the most effective treatment, notably for early stage pancreatic cancer cases.

Despite this, a previous study demonstrated that only 20% of patients present with localized and non-metastatic disease, and are therefore suitable for initial resection (2). Due to its specific tumor biology, pancreatic cancer is characterized with early recurrence and metastasis and resistance to chemotherapy and radiotherapy. The 5-year overall survival rate is <5% (3). Therefore, an improved understanding of the underlying mechanism of pancreatic cancer is required for the development of effective therapy and the improvement of patient survival.

Previously, the development of high throughput sequencing has resulted in the production of numerous gene expression profiles of neoplasms that are freely available via the Gene Expression Omnibus (GEO) database (4). Based on these data, the different aspects of the mechanism of pancreatic neoplasm development and the resistance to chemotherapy may be investigated. However, only a small part of these data has been used, and the majority of them have only been deposited. Using a bioinformatic analysis, these data may be re-analysed and used to provide valuable information for subsequent investigation. During the re-analysis process, differentially expressed genes (DEGs) are initially identified, and subsequently the functions and pathways of the genes involved are investigated. Several studies performed in pancreatic cancer have been performed previously (5,6). Although the majority of these studies only focused on the identification of the most significant genes, the tumor and normal tissues were not paired in those analyses. Therefore, in the present study, three GEO datasets were selected, which contained paired tumor tissues and corresponding normal tissues, and the microarray data was analysed. The analysis led to the identification of the DEGs, and Gene Ontology (GO) and pathway enrichment analysis were subsequently performed to explore the biological functions and pathways of these genes. Furthermore, a protein-protein interaction (PPI) network was constructed and a module analysis was performed to explore the hub genes in pancreatic cancer. The present study may provide novel insights into the understanding of the mechanism of pancreatic cancer formation and its corresponding hub genes, and the pathways involved may serve as potential targets for the treatment of this cancer type.

Materials and methods

Data source. The microarray data for the investigation of pancreatic cancer were downloaded from the GEO

Correspondence to: Dr Jianguo Guan, Department of Emergency Medicine, Anhui No. 2 Provincial People's Hospital, 1868 Danshan Road, Hefei, Anhui 230041, P.R. China
E-mail: guanjiangah@163.com

Key words: pancreatic cancer, bioinformatics analysis, differentially expressed gene, extracellular matrix

datasets (www.ncbi.nlm.nih.gov/geo) as follows: GSE15471, GSE16515 and GSE28735. The gene expression profiles of GSE15471 and GSE16515 were obtained using the GPL570 platform, and GSE28735 was obtained using the GPL6244 platform. GSE15471 and GSE28735 included 36 and 45 pairs of tumor and corresponding normal tissues, respectively. GSE16515 consisted of 36 tumor and 16 normal tissues. A total of 16 pairs of tissues were selected for subsequent analysis.

DEG identification. DEGs between tumor and normal tissue samples were identified using the online analysis tool GEO2R (www.ncbi.nlm.nih.gov/geo/geo2r), and the results were saved as a .txt format. The cut-off criteria for DEG identification were defined as adjusted $P < 0.05$ and \log_2 fold change (FC) > 1 . Subsequently, the DEGs of the three GEO datasets were processed to generate a Venn diagram using an online resource (bioinformatics.psb.ugent.be/webtools/Venn).

Gene Ontology (GO) and pathway enrichment analysis. To explore the primary functions and pathways of the DEGs involved, the Database for Annotation, Visualization and Integrated Discovery (DAVID; version 6.8; david.ncifcrf.gov) and the Panther (www.pantherdb.org) databases were employed to perform GO analysis. The Kyoto Encyclopedia of Genes and Genomes (7), and the Reactome pathway enrichment analysis were used for the pathway enrichment analysis (8-10). $P < 0.05$ and a DEG count ≥ 2 were set as criteria.

PPI network construction and module analysis. The Search Tool for the Retrieval of Interacting Genes (STRING; string-db.org) was used to build a PPI network, and subsequently the network was visualized using Cytoscape v3.6.1 software (11). The cut-off criterion for the PPI network was a combined score > 0.4 , and the hub genes were defined by a node degree > 10 . The modules of the PPI network were calculated using the Molecular Complex Detection (MCODE) plug-in of Cytoscape with default parameters. Subsequently, the hub genes in high-scored modules (degree cut-off=2, node score cut-off=0.2) were selected for additional GO and pathway enrichment analyses.

Results

Identification of DEGs in pancreatic cancer. Gene expression profiles from three pancreatic cancer GEO datasets were analysed. Based on the cut-off criteria, 1,666, 1,501 and 412 DEGs were extracted from the GSE15471, GSE16515 and GSE28735 datasets, respectively. Subsequently, 226 DEGs were identified (Fig. 1) by integrated bioinformatics analysis, including 179 upregulated and 47 downregulated DEGs (Table I).

GO analysis of DEGs in pancreatic cancer. Candidate DEGs function enrichment analysis was conducted with DAVID and Panther software. The functions of the DEGs were classified into three groups as follows: 'Cellular Component'; 'Molecular Function'; and 'Biological Process' (Fig. 2). DEGs were primarily involved in binding and catalytic activity with regard to the 'Molecular Function' group, cellular and metabolic processes with regard to the 'Biological Process' group, and cell membrane

with regard to the 'Cellular Component' group. Furthermore, the top 30 GO terms of these DEGs (Fig. 3), and the top 10 GO terms of the upregulated and downregulated DEGs were classified (Table II). The upregulated DEGs that were primarily enriched were associated with extracellular matrix (ECM) organisation, cell adhesion, collagen catabolic process and ECM disassembly in the 'Biological Process' group, whereas with regard to the 'Cellular Component' group ECM, extracellular space, extracellular region and extracellular exosome formation were the primary processes identified. The downregulated DEGs that were primarily enriched were associated with reactive oxygen species, metabolic processes, proteolysis and cellular response to starvation in the 'Biological Process' group. The enriched downregulated DEGs were also associated with extracellular exosome formation, extracellular space, integral component of plasma membrane and extracellular region with regard to the 'Cellular Component' group. These results indicated that the majority of DEGs were significantly enriched in processes, including extracellular exosome formation, ECM, ECM organisation, extracellular space and extracellular region.

Pathway enrichment analysis of DEGs in pancreatic cancer. The DEG signaling pathway enrichment was performed with DAVID. The 30 significantly enriched pathway terms are demonstrated in Fig. 4. The data indicated that these enriched genes were involved in matrix formation, activation of matrix metalloproteinase enzymes, ECM organisation, degradation of the ECM, ECM proteoglycan formation, non-integrin membrane-ECM interactions and ECM-receptor interaction. The data suggested that the DEGs primarily participated in the regulation of the ECM.

PPI network construction and module analysis. The PPI network of the DEGs was constructed according to the STRING database and subsequently visualized and analysed using Cytoscape. The results indicated that 163 genes, including 133 upregulated and 30 downregulated genes, of the 229 DEGs were filtered into the PPI network, and the PPI network complex contained 163 nodes and 438 edges (Fig. 5). Among the 163 nodes, 24 hub genes were identified with the following filter: Node degree > 10 . The top 10 most significant hub genes were albumin, epidermal growth factor, matrix metalloproteinase (MMP) 9, collagen type I $\alpha 2$ chain (COL1A2), fibronectin 1, collagen type I $\alpha 1$ chain (COL1A1), collagen type III $\alpha 1$ chain (COL3A1), tissue inhibitors of metalloproteinases 1 (TIMP1), integrin subunit $\alpha 2$ and MMP2. Subsequently, MCODE was used to determine the role of the hub genes, and the top 2 significant modules were selected for subsequent analysis. Module 1 consisted of 10 genes, whereas module 2 consisted of 7 genes. GO analysis indicated that module 1 was primarily associated with ECM disassembly and ECM formation, whereas module 2 was primarily associated with ECM organisation and ECM formation (Table III). Furthermore, pathway enrichment analysis demonstrated that module 1 was mainly enriched in the activation of matrix and the degradation of the ECM, whereas module 2 was mainly enriched in ECM proteoglycan formation, ECM-receptor interaction and ECM organisation (Table IV). These data indicated that the hub genes served key roles in the regulation of the ECM.

Table I. Identification of DEGs. A total of 226 DEGs were identified, including 179 upregulated genes and 47 downregulated genes.

DEGs	Gene names
Upregulated	ABHD17C, ACSL5, ADAM28, ADAM9, ADAMTS12, ADGRF1, AEBP1, AGR2, AHNK2, AK4, ANKRD22, ANLN, ANO1, ANTXR1, ANXA10, ANXA3, ANXA8, APOL1, AREG, ARNTL2, ASAP2, ASPM, BGN, CAPG, CCL18, CCL20, CD109, CDH11, CDH3, CEACAM1, CEACAM5, CEACAM6, CEMIP, CLDN18, COL10A1, COL11A1, COL12A1, COL1A1, COL1A2, COL3A1, COL5A2, COL8A1, COMP, CORIN, CP, CST1, CST2, CTHRC1, CTSE, CXCL5, DDX60, DGKH, DHRS9, DKK1, DPCR1, DPYSL3, ECT2, EDIL3, EDNRA, EFNA5, EFNB2, ENO2, EPHA4, EPHYC, ERO1A, ESM1, ETV1, FAP, FBXO32, FERMT1, FGD6, FN1, FOXQ1, FXYD3, GABRP, GALNT5, GCNT3, GJB2, GPRC5A, GPX2, GPX8, GREM1, HEPH, HK2, IFI27, IFI44L, IGF2BP3, IGFBP5, IL1R2, INHBA, INPP4B, ITGA2, ITGA3, ITGB4, KCNN4, KRT19, KRT7, KYNU, LAMA3, LAMB3, LAMC2, LCN2, LEF1, LOXL2, LRRN1, MALL, MATN3, MBOAT2, MELK, MET, MICAL2, MLPH, MMP1, MMP11, MMP12, MMP14, MMP7, MMP9, MTMR11, MXRA5, MYOF, NMU, NOX4, NPR3, NQO1, NRP2, NT5E, NTM, OAS1, OAS2, OLR1, OSBPL3, PCDH7, PGM2L1, PKM, PLA2R1, PLAC8, PLAT, PLAU, PLPP4, PLS1, POSTN, RAI14, RHBDL2, RUNX2, S100A16, S100P, SCEL, SCNN1A, SDR16C5, SERPINB3, SERPINB5, SLC22A3, SLC2A1, SLC44A4, SLC6A14, SLC6A6, SLPI, SRPX2, ST6GALNAC1, STYK1, SULF1, SULF2, SULT1C2, SYTL2, TCN1, TFF1, TGFBI, THBS2, TMC5, TMEM45B, TMPRSS4, TNFAIP6, TOP2A, TRIM29, TSPAN1, TSPAN8, VCAN, VSIG1
Downregulated	ABAT, ACADL, ADAMTS6, ALB, ANPEP, AOX1, BACE1, BNIP3, BTG2, C5, CHRM3, CTNND2, DPP10, EGF, EPB41L4B, EPHX2, ERO1B, F11, F8, FAM129A, FAM150B, FGL1, GATM, GNMT, GP2, GSTA1, HOMER2, IAPP, KIAA1324, LIFR, MCOLN3, MT1G, NR5A2, NUCB2, PAIP2B, PDK4, PNLIPRP1, RBPJL, RGN, SERPINI2, SLC16A10, SLC1A2, SLC39A5, SLC43A1, SLC4A4, TMED6, TRHDE

DEGs, differentially expressed genes.

Discussion

Pancreatic cancer is usually asymptomatic and is diagnosed in the advanced stages of progression due to lack of specific and sensitive detection markers that may be used during the early stages of the disease (12). The cancer cells are able to readily invade blood vessels and lymph nodes and metastasize to distant organs (13). Furthermore, pancreatic cancer is often resistant to conventional treatment, and it is characterised as one of the most lethal neoplasms (14). Previously, numerous studies have been performed to explore the underlying mechanism of pancreatic cancer progression and its treatment resistance. However, the disease prognosis has not changed significantly (15). The majority of these studies have focused on a single gene to investigate its potential role in pancreatic cancer, although cancer is a complex disease, and is not determined by only one or a few genes.

Therefore, the present study integrated three pancreatic cancer microarray datasets from different studies, using bioinformatics analysis. Consequently, 226 DEGs were identified, which included 176 upregulated and 47 downregulated genes. The function and pathway enrichment analysis were conducted, and the results indicated that these genes primarily participated in the ECM process. Furthermore, a PPI network was constructed in order to determine the role of the hub genes, and MCODE was used to determine the interactions




Figure 1. DEGs in pancreatic cancer microarray datasets. Venn diagram represents DEGs identified using three pancreatic cancer GEO datasets (GSE15471, GSE16515 and GSE28735). DEGs were identified using GEO2R with $P < 0.05$ and $|\log FC| > 1$. DEGs, differentially expressed genes. GEO, gene expression omnibus.

of these genes with several pathways. The results identified 24 hub genes among the 226 DEGs that were associated with ECM regulation.

Table II. Enrichment analysis of DEGs in pancreatic cancer.

DEGs	Term	Description	Category	P-value
Upregulated	GO:0030198	Extracellular matrix organization	BP	8.62x10 ⁻¹⁶
	GO:0031012	Extracellular matrix	CC	1.09x10 ⁻¹⁴
	GO:0007155	Cell adhesion	BP	2.15x10 ⁻¹⁴
	GO:0030574	Collagen catabolic process	BP	6.69x10 ⁻¹⁴
	GO:0005615	Extracellular space	CC	3.16x10 ⁻¹³
	GO:0005576	Extracellular region	CC	3.37x10 ⁻¹¹
	GO:0005578	Proteinaceous extracellular matrix	CC	1.11x10 ⁻¹⁰
	GO:0035987	Endodermal cell differentiation	BP	1.85x10 ⁻¹⁰
	GO:0070062	Extracellular exosome	CC	1.37x10 ⁻⁹
	GO:0022617	Extracellular matrix disassembly	BP	4.93x10 ⁻⁹
Downregulated	GO:0070062	Extracellular exosome	CC	5.19x10 ⁻⁶
	GO:0072593	Reactive oxygen species metabolic process	BP	9.67x10 ⁻⁵
	GO:0006508	Proteolysis	BP	1.62x10 ⁻³
	GO:0005615	Extracellular space	CC	5.84x10 ⁻³
	GO:0015171	Amino acid transmembrane transporter	MF	6.37x10 ⁻³
	GO:0009267	Cellular response to starvation	BP	6.44x10 ⁻³
	GO:0005887	Integral component of plasma membrane	CC	8.01x10 ⁻³
	GO:0031093	Platelet α granule lumen	CC	8.50x10 ⁻³
	GO:0016323	Basolateral plasma membrane	CC	1.05x10 ⁻²
	GO:0005576	Extracellular region	CC	1.77x10 ⁻²

DEGs, differentially expressed genes; CC, cellular component; MF, molecular function; BP, biological process.




Figure 2. GO analysis of the DEGs in pancreatic cancer. GO analysis classified the DEGs into three groups. Green, molecular function; red, cellular component, and blue, biological process. GO, gene ontology; DEG, differentially expressed genes.

Table III. Gene Ontology analysis of the top 2 modules genes.

Modules	Term	Description	Category	P-value
Module 1	GO:0004252	Serine-type endopeptidase activity	MF	7.34×10^{-6}
	GO:0022617	Extracellular matrix disassembly	BP	3.13×10^{-5}
	GO:0005576	Extracellular region	CC	5.57×10^{-5}
	GO:0070062	Extracellular exosome	CC	8.66×10^{-5}
	GO:0009986	Cell surface	CC	8.69×10^{-5}
	GO:0006508	Proteolysis	BP	2.14×10^{-4}
	GO:0005615	Extracellular space	CC	3.18×10^{-4}
	GO:0031093	Platelet α granule lumen	CC	3.31×10^{-4}
	GO:0031012	Extracellular matrix	CC	5.06×10^{-4}
	GO:0030574	Collagen catabolic process	BP	7.34×10^{-6}
Module 2	GO:0001501	Skeletal system development	BP	2.22×10^{-10}
	GO:0030198	Extracellular matrix organization	BP	1.22×10^{-9}
	GO:0031012	Extracellular matrix	CC	6.47×10^{-9}
	GO:0005615	Extracellular space	CC	1.61×10^{-7}
	GO:0005578	Proteinaceous extracellular matrix	CC	6.70×10^{-7}
	GO:0005201	Extracellular matrix structural	MF	1.19×10^{-6}
	GO:0007155	Cell adhesion	BP	7.91×10^{-6}
	GO:0005576	Extracellular region	CC	2.97×10^{-5}
	GO:0005518	Collagen binding	MF	1.85×10^{-4}
	GO:0030574	Collagen catabolic process	BP	2.12×10^{-4}

CC, cellular component; MF, molecular function; BP, biological process.




Figure 3. Significantly enriched GO terms in DEGs. Significantly enriched GO terms in DEGs identified in pancreatic cancer. Green, molecular function; red, cellular component, and blue, biological process. DEGs, differentially expressed genes; GEO, gene expression omnibus.

Table IV. Pathway enrichment analysis of the top 2 module genes.

Modules	Pathway	Name	P-value
Module 1	R-HSA-1592389	Activation of matrix	3.63x10 ⁻⁶
	R-HSA-1442490	Collagen degradation	1.71x10 ⁻³
	R-HSA-1474228	Degradation of the extracellular	2.52x10 ⁻³
	R-HSA-114608	Platelet degranulation	6.86x10 ⁻³
	R-HSA-75205	Dissolution of fibrin clot	1.28x10 ⁻²
	hsa04510	Focal adhesion	2.10x10 ⁻²
	hsa04810	Regulation of actin cytoskeleton	2.30x10 ⁻²
	R-HSA-210991	Basigin interactions	2.45x10 ⁻²
	R-HSA-3000157	Laminin interactions	2.94x10 ⁻²
	R-HSA-2022090	Assembly of collagen fibrils and other multimeric structures	4.47x10 ⁻²
Module 2	R-HSA-3000178	ECM proteoglycans	2.14x10 ⁻⁸
	R-HSA-216083	Integrin cell surface interactions	8.11x10 ⁻⁶
	hsa04512	ECM-receptor interaction	1.89x10 ⁻⁵
	R-HSA-1474244	Extracellular matrix organization	2.54x10 ⁻⁵
	R-HSA-3000170	Syndecan interactions	8.48x10 ⁻⁵
	R-HSA-3000171	Non-integrin membrane-ECM	1.88x10 ⁻⁴
	R-HSA-2022090	Assembly of collagen fibrils and other multimeric structures	2.49x10 ⁻⁴
	hsa04510	Focal adhesion	2.50x10 ⁻⁴
	R-HSA-1442490	Collagen degradation	4.83x10 ⁻⁴
	hsa04151	PI3K-Akt signaling pathway	1.14x10 ⁻³

CC, cellular component; MF, molecular function; BP, biological process; ECM, extracellular matrix; hsa, *Homo sapiens*.





Figure 4. Significantly enriched pathway terms in DEGs. Significant enriched pathway terms in DEGs identified in pancreatic cancer. Orange, Reactome analysis and blue, KEGG analysis. DEGs, differentially expressed genes; KEGG, kyoto encyclopedia of genes and genomes.

The ECM is a 3-dimensional non-cellular structure, which serves important roles in all tissues and biological process and is primarily responsible for the maintenance of tissue homeostasis and the regulation of development (16). As a complex network, the ECM consists of extracellular macromolecules, including

glycoproteins, collagen and enzymes, which provide structural support to the surrounding cells and segregate cells from one another. This sequesters a variety of cellular growth factors and regulates intercellular communication (17,18). Although the composition of the ECM varies between tissues and species, its



Although the ECM is responsible for regulating normal tissue development and homeostasis, its dysregulation also contributes to neoplastic progression. The development of cancer is significantly affected by the microenvironment and the ECM is considered the major component of tumor associated microenvironment (23). Although ECM remodelling is strictly regulated and mediated by the activities of specific enzymes, the dysregulation of these activities may account for the progression and development of certain disease conditions. This may lead to changes in the amount and composition of the ECM, which may significantly alter the biochemical properties of the ECM and promote the oncogenic effects of various pathways, and deregulate cell behaviours during malignant transformation (24). Several studies have suggested that the ECM is important for the maintenance of the polarity and architecture of tissues, and that deregulated ECM promotes epithelial-mesenchymal transition.

The present study revealed that the specific DEGs identified primarily participated in ECM formation, as demonstrated by analysis of specific hub genes, including *MMP2*, *MMP9*, *TIMP1*, *COL1A2*, *COL1A1* and *COL3A1*. MMPs are the primary enzymes that degrade the ECM and are synthesized by tumor cells (MMP7) or tumor stromal cells (MMP2 and MMP9). A previous study has demonstrated that MMPs serves important roles in cancer progression by increasing tumor cell migration, invasion, metastasis and angiogenesis (28). In pancreatic cancer, MMPs were correlated with prognosis, survival time, local invasion and distant metastasis (29). TIMPs are the endogenous inhibitors of MMPs, which bind to active and alternative sites of the activated MMP enzymes, prevent angiostatin and endostatin production, and serve a role in the promotion of tumor angiogenesis (30). The balance between MMPs and TIMPs may determine the ECM dynamics and affect tumor progression (31). *COL1A1*, *COL1A2* and *COL3A1* are the genes that encode collagen proteins, and the target genes of transforming growth factor- β (TGF- β)/SMAD3. Collagens mediate the tumor metastatic process via the interactions with MMPs and may also serve significant roles in the

immune response to cancer (32). β -TGF/SMAD3 may promote the expression of ECM-associated proteins (33). The aforementioned hub genes participated in ECM formation and may serve as potential targets for the treatment of pancreatic cancer.

Acknowledgements

Not applicable.

Funding

No funding was received.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

JG designed the study and revised the manuscript. KL performed the GEO database analysis, analysed the data and wrote the manuscript. JY and JS performed bioinformatics analyses and assisted with analysis of other data. All authors have read and approved the manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Siegel RL, Miller KD and Jemal A: Cancer statistics, 2018. *CA Cancer J Clin* 68: 7-30, 2018.
2. Gillen S, Schuster T, Meyer Zum Buschenfelde C, Friess H and Kleeff J: Preoperative/neoadjuvant therapy in pancreatic cancer: A systematic review and meta-analysis of response and resection percentages. *PLoS Med* 7: e1000267, 2010.
3. Kamisawa T, Wood LD, Itoi T and Takaori K: Pancreatic cancer. *Lancet* 388: 73-85, 2016.
4. Barrett T, Troup DB, Wilhite SE, Ledoux P, Rudnev D, Evangelista C, Kim IF, Soboleva A, Tomashevsky M and Edgar R: NCBI GEO: Mining tens of millions of expression profiles-database and tools update. *Nucleic Acids Res* 35: D760-D765, 2007.
5. Li J, Tan W, Peng L, Zhang J, Huang X, Cui Q, Zheng J, Tan W, Wu C and Lin D: Integrative analysis of gene expression profiles reveals specific signaling pathways associated with pancreatic duct adenocarcinoma. *Cancer Commun (Lond)* 38: 13, 2018.
6. Wang H, Zhan M, Yang R, Shi Y, Liu Q and Wang J: Elevated expression of NFE2L3 predicts the poor prognosis of pancreatic cancer patients. *Cell Cycle* 17: 2164-2174, 2018.
7. Kanehisa M, Sato Y, Furumichi M, Morishima K and Tanabe M: New approach for understanding genome variations in KEGG. *Nucleic Acids Res* 47: D590-D595, 2019.
8. Huang da W, Sherman BT and Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nat Protoc* 4: 44-57, 2009.
9. Huang da W, Sherman BT and Lempicki RA: Bioinformatics enrichment tools: Paths toward the comprehensive functional analysis of large gene lists. *Nucleic Acids Res* 37: 1-13, 2009.
10. Mi H, Huang X, Muruganujan A, Tang H, Mills C, Kang D and Thomas PD: PANTHER version 11: Expanded annotation data from Gene Ontology and Reactome pathways, and data analysis tool enhancements. *Nucleic Acids Res* 45: D183-D189, 2017.
11. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A software environment for integrated models of biomolecular interaction networks. *Genome Res* 13: 2498-2504, 2003.
12. Ilic M and Ilic I: Epidemiology of pancreatic cancer. *World J Gastroenterol* 22: 9694-9705, 2016.
13. Khadka R, Tian W, Hao X and Koirala R: Risk factor, early diagnosis and overall survival on outcome of association between pancreatic cancer and diabetes mellitus: Changes and advances, a review. *Int J Surg* 52: 342-346, 2018.
14. Kleeff J, Korc M, Apte M, La Vecchia C, Johnson CD, Biankin AV, Neale RE, Tempero M, Tuveson DA, Hruban RH and Neoptolemos JP: Pancreatic cancer. *Nat Rev Dis Primers* 2: 16022, 2016.
15. Cancer Research UK. Pancreatic cancer statistics 2015. <https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/pancreatic-cancer>. Accessed September 20, 2018.
16. Mammoto T and Ingber DE: Mechanical control of tissue and organ development. *Development* 137: 1407-1420, 2010.
17. Geiger B, Spatz JP and Bershadsky AD: Environmental sensing through focal adhesions. *Nat Rev Mol Cell Biol* 10: 21-33, 2009.
18. Theocharis AD, Skandalis SS, Gialeli C and Karamanos NK: Extracellular matrix structure. *Adv Drug Deliv Rev* 97: 4-27, 2016.
19. Abedin M and King N: Diverse evolutionary paths to cell adhesion. *Trends Cell Biol* 20: 734-742, 2010.
20. Engler AJ, Sen S, Sweeney HL and Discher DE: Matrix elasticity directs stem cell lineage specification. *Cell* 126: 677-689, 2006.
21. Gumbiner BM: Cell adhesion: The molecular basis of tissue architecture and morphogenesis. *Cell* 84: 345-357, 1996.
22. Hynes RO: The extracellular matrix: Not just pretty fibrils. *Science* 326: 1216-1219, 2009.
23. Lu P, Weaver VM and Werb Z: The extracellular matrix: A dynamic niche in cancer progression. *J Cell Biol* 196: 395-406, 2012.
24. Pickup MW, Mouw JK and Weaver VM: The extracellular matrix modulates the hallmarks of cancer. *EMBO Rep* 15: 1243-1253, 2014.
25. Radisky ES and Radisky DC: Matrix metalloproteinase-induced epithelial-mesenchymal transition in breast cancer. *J Mammary Gland Biol Neoplasia* 15: 201-212, 2010.
26. Avraamides CJ, Garmy-Susini B and Varner JA: Integrins in angiogenesis and lymphangiogenesis. *Nat Rev Cancer* 8: 604-617, 2008.
27. Sorokin L: The impact of the extracellular matrix on inflammation. *Nat Rev Immunol* 10: 712-723, 2010.
28. Egeblad M and Werb Z: New functions for the matrix metalloproteinases in cancer progression. *Nat Rev Cancer* 2: 161-174, 2002.
29. Garcea G, Neal CP, Pattenden CJ, Steward WP and Berry DP: Molecular prognostic markers in pancreatic cancer: A systematic review. *Eur J Cancer* 41: 2213-2236, 2005.
30. Jiang Y, Goldberg ID and Shi YE: Complex roles of tissue inhibitors of metalloproteinases in cancer. *Oncogene* 21: 2245-2252, 2002.
31. Bonnans C, Chou J and Werb Z: Remodelling the extracellular matrix in development and disease. *Nat Rev Mol Cell Biol* 15: 786-801, 2014.
32. Nerenberg PS, Salsas-Escat R and Stultz CM: Collagen - A necessary accomplice in the metastatic process. *Cancer Genomics Proteomics* 4: 319-327, 2007.
33. Verrecchia F, Chu ML and Mauviel A: Identification of novel TGF-beta /Smad gene targets in dermal fibroblasts using a combined cDNA microarray/promoter transactivation approach. *J Biol Chem* 276: 17058-17062, 2001.



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.